Board of Directors

Gene Hsu

Gene Hsu is the chairman and CEO of Xgene Pharmaceutical Inc. Prior to Xgene Pharmaceutical Inc., Dr. Hsu was the Senior Vice President of HEC Pharm Group, Chief Scientific Officer of Shanghai InnoStar Biotech Co., and a Vice President at TaiGen Biotechnology Co. His professional experience includes technical and leadership positions at Merck & Co., Inc., the U.S. Environmental Protection Agency, and the California EPA. Dr. Hsu has led and/or participated in more than 50 IND submissions to FDA and China FDA. Dr. Hsu was the President of American Association of Chinese in Toxicology. He has authored/co-authored over 150 scientific publications, book chapters, and technical reports and co-edited Cancer Risk Assessment (John Wiley & Sons, Inc.). Dr. Hsu earned his Ph.D. from the Massachusetts Institute of Technology. He completed his postdoctoral training at the University of California at Berkeley. He is board-certified in toxicology by the American Board of Toxicology.

Feng Xu

Feng Xu has a more than 20 year track record in drug discovery in the biopharmaceutical industry. Most recently, Dr. Xu was the founder and CEO of Kyphia Pharmaceuticals where he oversaw drug discovery efforts in the cancer and pain. During his previous, 9 year tenure at Xenoport, he oversaw a number of drug discovery programs in the areas of pain and CNS disease. He is an inventor on over 20 issued patents and has co-authored 30 publications Dr. Xu received his Ph.D. from Boston University and completed postdoctoral studies in the laboratories of Professor E. J. Corey (Nobel Laureate) at Harvard University.

Stephen Ip
Independent Director

Dr. Ip applies his more than 30 years of experience ranging across biotech start-ups and listed, public pharmaceutical companies to a focus on business development and licensing opportunities. He has concluded deals and joint ventures with SmithKline Beecham, Yamanouchi, Mitsubishi, P&G Pharmaceuticals, Sysmex, Astra, Chiron, Pfizer, Syntex, Purdue Pharmaceutical, MBL Laboratories, and Bio-Rad Laboratories. He was a founding member of Cambridge Research Laboratories (Ortho, a Johnson and Johnson company) and T Cell Sciences. He served as President and Chief Operating Office with American Biogenetic Science, CytoMed, International Bioimmune System and Senior Vice President of Business Development with TaiGen Biotechnology, Matritech, and T Cell Sciences. Dr. Ip received his Ph.D. from University of Virginia Medical School and served as an NIH postdoctoral fellow in Hematology and Oncology at University of Pennsylvania Medical School. He was appointed Adj. Associate Professor at Columbia Medical School (Pathology).

Lily Shen


Morningside Ventures

Ms. Lily Shen is a Managing Director with Morningside Ventures. She serves on the boards of more than ten biotech companies. Before joining Morningside in 2010, she worked at two biotech companies covering BD and regulatory affairs in China. Ms. Lily Shen holds Master degree in Molecular Biology from Xi’an Jiaotong University and an M.B.A. degree from Fudan University.

Wei Lu


Ping An Ventures

Ms. Wei Lu is the Vice President of Ping An Ventures with10+ years of experience in private equity investment and post investment management. In Ping An ventures, she is mainly responsible for the post investment management of medical investment. The invested enterprises mainly include biotechnology, medical devices, medical services, etc.


Ms. Wei Lu holds Master’s degree in Finance from Chongqing University.

Ning Xue


Hengxu Capital

Mr. Ning Xue, the managing director of Hengxu Capital, is responsible for healthcare investments. Previously worked at CPE and PAG, he has led dozens of investment projects in the healthcare field with a total amount of 5 billion Chinese Yuan. He has been in charge of numerous star investment projects to BeiGene, RemeGen, and Alphamab Oncology etc., and has led multiple M&A, privatization, and backdoor listing projects, including the privatization of 3SBio Inc. and the backdoor listing of Youbo Pharmaceutical Co., Ltd. Via Jiuzhitang Co., Ltd.. Mr. Ning has a wealth of-experience resource in medical field development, enterprise IPO, and operating systems design.